Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri
01 Maio 2023 - 10:30AM
Business Wire
Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a
health tech company that develops and commercializes bioelectronic
medicine, today announced the appointment of veteran Kimberly
Bambach to serve as Interim Chief Financial Officer of the company
and the engagement of Christina Valauri as a strategic advisor to
the Board of Directors. These additions aim to strengthen the
company's financial foundation and bring growth and M&A
expertise to the team.
Ms. Bambach brings over 30 years of financial leadership
experience in both public and private companies across industries.
Her background includes financial leadership in medical and retail
markets, manufacturing, wholesale distribution, licensing, digital
media, and broadcasting. Bambach most recently served as Chief
Financial Officer of Jushi Holdings Inc., where she played a
pivotal role in the company's rapid growth driving over a dozen
acquisitions in a complex regulatory environment. Since leaving
Jushi as CFO, Bambach has continued as an advisor to the company
while providing consulting services to several private companies.
Before Jushi, Ms. Bambach held executive leadership and finance
positions in both public and private equity companies. She replaces
Veronica Cai, who served as Chief Financial Officer of the Company
since April 2022. Ms. Bambach holds a BA from SUNY Brockport and an
MBA from Pace University.
“I am pleased to have such an experienced financial leader join
our leadership team,” said Jennifer Ernst, CEO of Tivic. “As we
prepare Tivic for the future in a rapidly evolving health tech
market, I am confident that Kimberly's strong leadership and
expertise in financial and operational improvements will have an
immediate positive impact on our company.”
Ms. Valauri will serve as a strategic advisor to Tivic’s board
of directors. She brings a 30 year proven track record as a senior
healthcare analyst, including leadership roles as US and Global
Head of Equity Research and Managing Director at Cantor Fitzgerald.
Ms. Valauri is the founding partner and CEO of Sagestone Advisory,
LLC and a partner of NextGen Venture Partners, an early stage
venture capital firm with a network of 1600 proven entrepreneurs
and accomplished professionals. Her background in equity securities
research has provided a deep base of experience in pharmaceutical,
biotech, and med-tech companies. She has extensive experience
identifying and analyzing the commercial potential of breakthrough
innovations, as well as mentoring and advising the C-suite teams of
private and public early-stage healthcare companies through product
development, regulatory, go-to-market strategies, potential mergers
and acquisitions, and IPOs. She has successfully developed and
executed transformational business strategies to drive growth and
enhance operating performance.
Ms. Valauri has previously held senior roles at US and
international firms including ING, Credit Lyonnais (acquired by
Credit Agricole), Natixis, and was the Global Director of Research
for Cantor Fitzgerald. She has been recognized by The Wall Street
Journal’s “Best on The Street” All Star Analyst Survey and has
received the Award for Excellence - Medical Education Public
Affairs Association of American - Medical Colleges - New York
University. She currently serves as a senior advisor with Hanover
International, Inc., Astia.org, and as a mentor and advisor at the
Weill Cornell Medicine BioVenture eLab. Ms. Valauri earned her BA
in Biology from Reed College and MBA from Cornell University.
“The Board and I value the astute insight and understanding of
emerging growth companies Christina is bringing to this board
advisory role,” said Jennifer Ernst, CEO of Tivic. “Christina is a
seasoned financial steward and her expertise will be invaluable to
our evaluation of transformational growth opportunities through
internal development, strategic partnerships and M&A to drive
value for our shareholders and customers.”
About Tivic
Tivic is a commercial health tech company advancing the field of
bioelectronic medicine. Tivic’s patented technology platform
leverages stimulation on the trigeminal, sympathetic, and vagus
nerve structures. Tivic’s non-invasive and targeted approach to the
treatment of inflammatory chronic health conditions gives consumers
and providers drug-free therapeutic solutions with high safety
profiles, low risk, and broad applications. Tivic’s first
commercial product ClearUP is an FDA approved, award-winning,
handheld bioelectronic sinus device. ClearUP is clinically proven,
doctor-recommended, and is available through online retailers and
commercial distributors. For more information visit
http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. For a discussion of
other risks and uncertainties, and other important factors, any of
which could cause Tivic’s actual results to differ from those
contained in the forward-looking statements, see Tivic’s filings
with the SEC, including, its Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the SEC on March 31, 2023,
under the heading “Risk Factors”; as well as the company’s
subsequent filings with the SEC. Forward-looking statements
contained in this press release are made as of this date, and Tivic
Health Systems, Inc. undertakes no duty to update such information
except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005317/en/
Media Contact: Kayleigh Westerfield 949-632-3439
Kayleigh.Westerfield@tivichealth.com
Investor Contact: Hanover International, Inc.
ir@tivichealth.com
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024